Wong WL, Su X, Li X et al (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2:e106–e116

Article  PubMed  Google Scholar 

Blasiak J, Piechota M, Pawlowska E et al (2017) Cellular senescence in age-related macular degeneration: can autophagy and DNA damage response play a role? Oxid Med Cell Longev 2017:5293258. https://doi.org/10.1155/2017/5293258

Article  CAS  PubMed  PubMed Central  Google Scholar 

Blasiak J, Glowacki S, Kauppinen A, Kaarniranta K (2013) Mitochondrial and nuclear DNA damage and repair in age-related macular degeneration. Int J Mol Sci 14:2996–3010

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chalam KV, Khetpal V, Rusovici R, Balaiya S (2011) A review: role of ultraviolet radiation in age-related macular degeneration. Eye Contact Lens 37:225–232

Article  CAS  PubMed  Google Scholar 

Kozhevnikova OS, Korbolina EE, Ershov NI, Kolosova NG (2013) Rat retinal transcriptome: effects of aging and AMD-like retinopathy. Cell Cycle 12:1745–1761

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang S, Wang X, Cheng Y et al (2019) Autophagy dysfunction, cellular senescence, and abnormal immune-inflammatory responses in AMD: from mechanisms to therapeutic potential. Oxid Med Cell Longev 2019:3632169. https://doi.org/10.1155/2019/3632169

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chappelow AV, Kaiser PK (2008) Neovascular age-related macular degeneration: potential therapies. Drugs 68:1029–1036

Article  CAS  PubMed  Google Scholar 

Amoaku WM, Chakravarthy U, Gale R et al (2015) Defining response to anti-VEGF therapies in neovascular AMD. Eye 29:721–731

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharma A, Kumar N, Kuppermann BD et al (2020) Faricimab: expanding horizon beyond VEGF. Eye 34:802–804

Article  PubMed  Google Scholar 

Campochiaro PA, Peters KG (2016) Targeting Tie2 for treatment of diabetic retinopathy and diabetic macular edema. Curr Diab Rep 16:1–11

Article  CAS  Google Scholar 

Parikh SM (2017) The Angiopoietins and Tie2 in Vascular Inflammation. Curr Opin Hematol 24:432

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saharinen P, Eklund L, Alitalo K (2017) Therapeutic targeting of the angiopoietin–TIE pathway. Nat Rev Drug Discov 16:635–661

Article  CAS  PubMed  Google Scholar 

Huang H, Bhat A, Woodnutt G, Lappe R (2010) Targeting the ANGPT–TIE2 pathway in malignancy. Nat Rev Cancer 10:575–585

Article  CAS  PubMed  Google Scholar 

Regula JT, Lundh von Leithner P, Foxton R et al (2019) Targeting key angiogenic pathways with a bispecific Cross MA b optimized for neovascular eye diseases. EMBO Mol Med 11:e10666

Article  PubMed  PubMed Central  Google Scholar 

Regula JT, Lundh von Leithner P, Foxton R et al (2016) Targeting key angiogenic pathways with a bispecific Cross MA b optimized for neovascular eye diseases. EMBO Mol Med 8:1265–1288

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heier JS, Singh RP, Wykoff CC et al (2021) The Angiopoietin/Tie pathway in retinal vascular diseases: a review. Retina 41:1–19

Article  CAS  PubMed  Google Scholar 

Shirley M (2022) Faricimab: first approval. Drugs 82:825–830

Article  CAS  PubMed  Google Scholar 

Ferro Desideri L, Traverso CE, Nicolò M, Munk MR (2023) Faricimab for the treatment of diabetic macular edema and neovascular age-related macular degeneration. Pharmaceutics 15:1413

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wykoff CC, Abreu F, Adamis AP et al (2022) Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. The Lancet 399:741–755

Article  CAS  Google Scholar 

Heier JS, Khanani AM, Ruiz CQ et al (2022) Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. The Lancet 399:729–740

Article  CAS  Google Scholar 

Abdin AD, Aljundi W, El Jawhari K et al (2022) First year real life experience with intravitreal brolucizumab for treatment of refractory neovascular age-related macular degeneration. Front Pharmacol 13:860784

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abdin AD, Mohamed A, Munteanu C et al (2021) Intravitreal aflibercept following treat and extend protocol versus fixed protocol for treatment of neovascular age-related macular degeneration. Int J Retina Vitreous 7:1–5

Article  Google Scholar 

Abdin AD, Suffo S, Asi F et al (2019) Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 257:1671–1677

Article  CAS  PubMed  Google Scholar 

Abdin AD, Suffo S, Bischoff-Jung M et al (2020) Advantages of a designated IVI center for a German university eye hospital. Ophthalmologe 117:50–57

Article  PubMed  Google Scholar 

Aljundi W, Gradinger F, Langenbucher A et al (2023) Choroidal thickness as a possible predictor of non-response to intravitreal bevacizumab for macular edema after retinal vein occlusion. Sci Rep 13:451

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mettu PS, Allingham MJ, Cousins SW (2021) Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. Prog Retin Eye Res 82:100906

Article  CAS  PubMed  Google Scholar 

Khanna S, Komati R, Eichenbaum DA et al (2019) Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. BMJ Open Ophthalmol 4:e000398

Article  PubMed  PubMed Central  Google Scholar 

Khan M, Aziz AA, Shafi NA et al (2020) Targeting angiopoietin in retinal vascular diseases: a literature review and summary of clinical trials involving faricimab. Cells 9:1869

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sahni J, Patel SS, Dugel PU et al (2019) Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial. Ophthalmology 126:1155–1170

Article  PubMed  Google Scholar 

Khanani AM, Patel SS, Ferrone PJ et al (2020) Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial. JAMA Ophthalmol 138:964–972

Article  PubMed  PubMed Central  Google Scholar 

Sahni J, Dugel PU, Patel SS et al (2020) Safety and efficacy of different doses and regimens of faricimab vs ranibizumab in neovascular age-related macular degeneration: the AVENUE phase 2 randomized clinical trial. JAMA Ophthalmol 138:955–963

Article  PubMed  Google Scholar 

Okada M, Mitchell P, Finger RP et al (2021) Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review. Ophthalmology 128:234–247

Article  PubMed  Google Scholar 

Khanani AM, Aziz AA, Khan H et al (2023) The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study–6 month results. Eye 37:3574–3581. https://doi.org/10.1038/s41433-023-02553-5

Article  CAS  PubMed  PubMed Central  Google Scholar 

Foss A, Rotsos T, Empeslidis T, Chong V (2022) Development of macular atrophy in patients with wet age-related macular degeneration receiving anti-VEGF treatment. Ophthalmologica 245:204–217

Article  CAS  PubMed  Google Scholar 

Munk MR, Ceklic L, Ebneter A et al (2016) Macular atrophy in patients with long-term anti-VEGF treatment for neovascular age-related macular degeneration. Acta Ophthalmol 94:e757–e764

Article  CAS  PubMed  Google Scholar 

Horani M, Mahmood S, Aslam TM (2020) A review of macular atrophy of the retinal pigment epithelium in patients with neovascular age-related macular degeneration: what is the link? Part ii. Ophthalmol Ther 9:35–75

Article  PubMed  PubMed Central